SCHEMBL4811550

SCHEMBL4811550

O=C1C=C(I)CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3974043 0.82
SCHEMBL275931 0.67
SCHEMBL1374641 0.67
SCHEMBL355337 0.67
SCHEMBL31955606 0.67 MAPT (0.44)
SCHEMBL124901 0.67
SCHEMBL9712110 0.67
SCHEMBL9613581 0.67
SCHEMBL215853 0.67
SCHEMBL678750 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112679328-B Industrial production method of 3-trifluoromethyl-2-cyclohexene-1-one 南京药石科技股份有限公司 2023-09-15 CN claimed
CN-112679328-A Industrial production method of 3-trifluoromethyl-2-cyclohexene-1-ketone 南京药石科技股份有限公司 2021-04-20 CN claimed
US-20240400501-A1 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF ALLERGAN, INC. 2024-12-05 US disclosed
US-RE49934-E1 Inhibitors of cellular metabolic processes SERVIER PHARMACEUTICALS LLC (US) 2024-04-23 US disclosed
CN-112679328-B Industrial production method of 3-trifluoromethyl-2-cyclohexene-1-one 南京药石科技股份有限公司 2023-09-15 CN disclosed
US-20220402866-A1 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF ALLERGAN, INC. 2022-12-22 US disclosed
US-20220402866-A1 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF ALLERGAN, INC. 2022-12-22 US disclosed
CN-109890822-B Inhibitors of cellular metabolic processes 安吉奥斯医药品有限公司 2022-08-30 CN disclosed
US-11325914-B1 Inhibitors of cellular metabolic processes SERVIER PHARMACEUTICALS LLC (US) 2022-05-10 US disclosed
US-11325914-B1 Inhibitors of cellular metabolic processes SERVIER PHARMACEUTICALS LLC (US) 2022-05-10 US disclosed
US-11208377-B2 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof ALLERGAN, INC. (US) 2021-12-28 US disclosed
US-7384580-B2 Method of preparing organomagnesium compounds LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) 2008-06-10 US disclosed
US-7384580-B2 Method of preparing organomagnesium compounds LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) 2008-06-10 US disclosed
US-20070194468-A1 Method of preparing organomagnesium compounds LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) 2007-08-23 US disclosed
US-20070194468-A1 Method of preparing organomagnesium compounds LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) 2007-08-23 US disclosed
US-20070194468-A1 Method of preparing organomagnesium compounds LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) 2007-08-23 US disclosed
US-20050218532-A1 Method of preparing organomagnesium compounds LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) 2005-10-06 US disclosed
EP-1582524-A1 Method of preparing organomagnesium compounds Ludwig Maximilians Universität (DE) 2005-10-05 EP disclosed
EP-1582523-A1 Method of preparing organomagnesium compounds Ludwig-Maximilians-Universität München (DE) 2005-10-05 EP disclosed
EP-0737329-B1 TABULAR GRAIN EMULSIONS WITH SELECTED SITE HALIDE CONVERSIONS AND PROCESSES FOR THEIR PREPARATION EASTMAN KODAK CO (US) 2002-04-03 EP disclosed